Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-058672
Filing Date
2024-05-13
Accepted
2024-05-13 16:16:32
Documents
56
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tern-20240331.htm   iXBRL 10-Q 1331493
2 EX-10.1 tern-ex10_1.htm EX-10.1 33741
3 EX-10.2 tern-ex10_2.htm EX-10.2 124092
4 EX-31.1 tern-ex31_1.htm EX-31.1 15789
5 EX-31.2 tern-ex31_2.htm EX-31.2 15786
6 EX-32.1 tern-ex32_1.htm EX-32.1 8793
7 EX-32.2 tern-ex32_2.htm EX-32.2 8793
  Complete submission text file 0000950170-24-058672.txt   7557452

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tern-20240331.xsd EX-101.SCH 1383694
60 EXTRACTED XBRL INSTANCE DOCUMENT tern-20240331_htm.xml XML 1309421
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39926 | Film No.: 24939285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)